TY - JOUR
T1 - Prospective cohort study of influenza vaccine effectiveness among healthcare personnel in Lima, Peru
T2 - Estudio Vacuna de Influenza Peru, 2016-2018
AU - Wesley, Meredith G.
AU - Soto, Giselle
AU - Arriola, Carmen Sofia
AU - Gonzales, Miriam
AU - Newes-Adeyi, Gabriella
AU - Romero, Candice
AU - Veguilla, Vic
AU - Levine, Min Z.
AU - Silva, Maria
AU - Ferdinands, Jill M.
AU - Dawood, Fatimah S.
AU - Reynolds, Sue B.
AU - Hirsch, Avital
AU - Katz, Mark
AU - Matos, Eduardo
AU - Ticona, Eduardo
AU - Castro, Juan
AU - Castillo, Maria
AU - Bravo, Eduar
AU - Cheung, Angela
AU - Phadnis, Rachel
AU - Martin, Emily Toth
AU - Tinoco, Yeny
AU - Neyra Quijandria, Joan Manuel
AU - Azziz-Baumgartner, Eduardo
AU - Thompson, Mark G.
AU - Sambhara, Suryaprakash
AU - Gangappa, Shivaprakash
AU - Malosh, Ryan E.
AU - Flygare, Christopher
AU - Cao, Weiping
AU - Mishina, Margarita
AU - Yoo, Young Moo
AU - Mores, Christopher N.
AU - Campbell, Wesley R.
N1 - Publisher Copyright:
© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Background: The Estudio Vacuna de Influenza Peru (VIP) cohort aims to describe the frequency of influenza virus infection, identify predictors of vaccine acceptance, examine the effects of repeated influenza vaccination on immunogenicity, and evaluate influenza vaccine effectiveness among HCP. Methods: The VIP cohort prospectively followed HCP in Lima, Peru, during the 2016-2018 influenza seasons; a fourth year is ongoing. Participants contribute blood samples before and after the influenza season and after influenza vaccination (for vaccinees). Weekly surveillance is conducted to identify acute respiratory or febrile illnesses (ARFI). When an ARFI is identified, participants self-collect nasal swabs that are tested for influenza viruses by real-time reverse transcriptase-polymerase chain reaction. Influenza vaccination status and 5-year vaccination history are ascertained. We analyzed recruitment and enrollment results for 2016-2018 and surveillance participation for 2016-2017. Results: In the first 3 years of the cohort, VIP successfully contacted 92% of potential participants, enrolled 76% of eligible HCP, and retained >90% of participants across years. About half of participants are medical assistants (54%), and most provide “hands-on” medical care (76%). Sixty-nine percent and 52% of participants completed surveillance for >70% of weeks in years 1 and 2, respectively. Fewer weeks of completed surveillance was associated with older age (≥50 years), being a medical assistant, self-rated health of fair or poor, and not receiving the influenza vaccine during the current season (P-values <.05). Conclusions: The VIP cohort provides an opportunity to address knowledge gaps about influenza virus infection, vaccination uptake, effectiveness and immunogenicity among HCP.
AB - Background: The Estudio Vacuna de Influenza Peru (VIP) cohort aims to describe the frequency of influenza virus infection, identify predictors of vaccine acceptance, examine the effects of repeated influenza vaccination on immunogenicity, and evaluate influenza vaccine effectiveness among HCP. Methods: The VIP cohort prospectively followed HCP in Lima, Peru, during the 2016-2018 influenza seasons; a fourth year is ongoing. Participants contribute blood samples before and after the influenza season and after influenza vaccination (for vaccinees). Weekly surveillance is conducted to identify acute respiratory or febrile illnesses (ARFI). When an ARFI is identified, participants self-collect nasal swabs that are tested for influenza viruses by real-time reverse transcriptase-polymerase chain reaction. Influenza vaccination status and 5-year vaccination history are ascertained. We analyzed recruitment and enrollment results for 2016-2018 and surveillance participation for 2016-2017. Results: In the first 3 years of the cohort, VIP successfully contacted 92% of potential participants, enrolled 76% of eligible HCP, and retained >90% of participants across years. About half of participants are medical assistants (54%), and most provide “hands-on” medical care (76%). Sixty-nine percent and 52% of participants completed surveillance for >70% of weeks in years 1 and 2, respectively. Fewer weeks of completed surveillance was associated with older age (≥50 years), being a medical assistant, self-rated health of fair or poor, and not receiving the influenza vaccine during the current season (P-values <.05). Conclusions: The VIP cohort provides an opportunity to address knowledge gaps about influenza virus infection, vaccination uptake, effectiveness and immunogenicity among HCP.
KW - healthcare personnel
KW - influenza
KW - influenza vaccine
UR - http://www.scopus.com/inward/record.url?scp=85082978086&partnerID=8YFLogxK
U2 - 10.1111/irv.12737
DO - 10.1111/irv.12737
M3 - Artículo
C2 - 32249553
AN - SCOPUS:85082978086
SN - 1750-2640
VL - 14
SP - 391
EP - 402
JO - Influenza and other Respiratory Viruses
JF - Influenza and other Respiratory Viruses
IS - 4
ER -